Antonio Calcagni1,2,3, Olivia Howells4,5, Hannah Bartlett6, Alastair K O Denniston5,7, Jonathan M Gibson4,5, Christopher R Hogg8, Timothy D Matthews5, Frank Eperjesi4,9. 1. Aston University, School of Life and Health Sciences, Birmingham, UK. a.calcagni@aston.ac.uk. 2. University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. a.calcagni@aston.ac.uk. 3. Moorfields Eye Hospital NHS Foundation Trust, London, UK. a.calcagni@aston.ac.uk. 4. Aston University, School of Life and Health Sciences, Birmingham, UK. 5. University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. 6. Aston University, School of Life and Health Sciences, Birmingham, UK. h.e.bartlett@aston.ac.uk. 7. Academic Unit of Ophthalmology, University of Birmingham, Birmingham, UK. 8. Moorfields Eye Hospital NHS Foundation Trust, London, UK. 9. Department of Health Science, Arab American University, Ramallah, Palestine.
Abstract
BACKGROUND: Neovascular age-related macular degeneration (nAMD) is a leading cause of blind registrations in the elderly. Unfortunately, it is difficult to detect the early stage of the disease, when treatment is more likely to be successful. Subjects with very early disease are likely to have abnormal macular function, even in the pre-symptomatic stage. In this study, colour vision was evaluated to establish if subjects at high risk of developing nAMD can be identified, thus allowing earlier diagnosis and possible treatment. METHODS: Colour contrast sensitivity (CCS) was evaluated over time in the fellow unaffected eye of subjects with unilateral nAMD. Participants were divided into Group 1 (182 participants) or Group 2 (15 participants) according to whether nAMD did not or did develop in the study period respectively and the two groups were compared. RESULTS: CCS was increased (i.e. worse colour vision) compared with the age-matched reference range in a high proportion of fellow eyes in both Groups 1 and 2. Global mean CCS values did not show statistically significant differences between the two groups. However, there was a statistically significant difference between mean Group 1 CCS values and the last CCS value prior to nAMD diagnosis from Group 2 subjects. CONCLUSION: This study shows that in patients with unilateral nAMD, colour vision is frequently abnormal in the fellow unaffected eye. Abnormal CCS does not predict the development of nAMD within the 12 month period of the study and therefore it is not a viable screening tool for this pathology.
BACKGROUND: Neovascular age-related macular degeneration (nAMD) is a leading cause of blind registrations in the elderly. Unfortunately, it is difficult to detect the early stage of the disease, when treatment is more likely to be successful. Subjects with very early disease are likely to have abnormal macular function, even in the pre-symptomatic stage. In this study, colour vision was evaluated to establish if subjects at high risk of developing nAMD can be identified, thus allowing earlier diagnosis and possible treatment. METHODS: Colour contrast sensitivity (CCS) was evaluated over time in the fellow unaffected eye of subjects with unilateral nAMD. Participants were divided into Group 1 (182 participants) or Group 2 (15 participants) according to whether nAMD did not or did develop in the study period respectively and the two groups were compared. RESULTS: CCS was increased (i.e. worse colour vision) compared with the age-matched reference range in a high proportion of fellow eyes in both Groups 1 and 2. Global mean CCS values did not show statistically significant differences between the two groups. However, there was a statistically significant difference between mean Group 1 CCS values and the last CCS value prior to nAMD diagnosis from Group 2 subjects. CONCLUSION: This study shows that in patients with unilateral nAMD, colour vision is frequently abnormal in the fellow unaffected eye. Abnormal CCS does not predict the development of nAMD within the 12 month period of the study and therefore it is not a viable screening tool for this pathology.
Authors: David S Boyer; Andrew N Antoszyk; Carl C Awh; Robert B Bhisitkul; Howard Shapiro; Nisha R Acharya Journal: Ophthalmology Date: 2007-02 Impact factor: 12.079
Authors: Melissa M Brown; Gary C Brown; Joshua D Stein; Zachary Roth; Joseph Campanella; George R Beauchamp Journal: Can J Ophthalmol Date: 2005-06 Impact factor: 1.882
Authors: Christopher G Owen; Zakariya Jarrar; Richard Wormald; Derek G Cook; Astrid E Fletcher; Alicja R Rudnicka Journal: Br J Ophthalmol Date: 2012-02-13 Impact factor: 4.638